Efficacy and Safety Study of LAS41007 in the Treatment of Actinic Keratosis
The aim of this study is to determine the efficacy, safety and tolerability of either a once or twice daily topical application of LAS41007 compared to a twice daily application of LAS106521 in the treatment of actinic keratosis.
Actinic Keratosis
DRUG: LAS41007 o.d.|DRUG: LAS41007 b.i.d.|DRUG: LAS106521
Histological clearance of one pre-selected target lesion, Day 120|Complete clinical clearance of all target lesions in the treatment areas, Day 120
Physician's Global Tolerability Assessment (PGT), Day 120
The aim of this study is to determine the efficacy, safety and tolerability of either a once or twice daily topical application of LAS41007 compared to a twice daily application of LAS106521 in the treatment of actinic keratosis.